- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02182128
A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours
A Phase I Open-label Dose-escalation Study of Continuous Twice-daily Oral Treatment With BIBF 1120 in Japanese Patients With Advanced Solid Tumours
Studienübersicht
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female patients with a confirmed diagnosis of an advanced, non resectable and/or metastatic solid tumour (except for malignant lymphoma)
- Patients who have not responded to conventional treatment, or for whom no therapy of proven efficacy was available, or who were not amenable to established forms of treatment
Patients recovered from any therapy-related toxicities from previous chemo-, hormone-, immuno-, or radio-therapies (except for epilation) at least over the following periods of time:
- four weeks after chemotherapy (at least 2 weeks after receiving antimetabolite or at least 6 weeks after nitrosourea or mitomycin C)
- two weeks after receiving hormone therapy
- four weeks after receiving radiation therapy (2 weeks after radiation for symptom control)
- two weeks after receiving immunotherapy
- four weeks after surgical procedures
- Age 20 years or older
- Life expectancy of at least 3 months
- Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2
Patients retaining a significant physiological compensatory function and without manifest marked disorders of the hematopoietic system, heart, lung, liver, kidneys, etc., i.e., patients with sufficient baseline organ function
- An absolute neutrophil count more than 1500/mm3
- A platelet count more than 100000/mm3
- A haemoglobin count more than 9.0 g/dL
- Serum creatinine less than 1.5-fold the upper limit value of the normal range
- Bilirubin less than 1.5-fold the upper limit value of the normal range
- Activities of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) less than 1.5-fold the upper limit value of normal range (if related to liver metastases less than 2.5-fold the upper limit value of the normal range)
- Saturation pulse oxygen (SpO2) level not less than 90%
- No participation in other clinical trials within 4 weeks before start of therapy within this trial
- Written informed consent given that is consistent with ICH-GCP guidelines
Exclusion criteria
- Brain tumour, and/or brain metastases requiring therapy
- History of obvious pulmonary fibrosis or interstitial pneumonitis in chest X-ray including pneumoconiosis or radiation-induced pulmonary fibrosis expanding out of radiation field
- Patients with difficulty in swallowing study medication
- Gastrointestinal disorders that might interfere with the absorption of the study drug (Crohn's disease, ulcerative colitis, broad resection of the stomach)
- Patients with diarrhoea greater than CTCAE grade 2
- Patients within 4 weeks after major surgical procedures or patients with active ulcers or with injuries with incomplete wound healing
- History of autoimmune disease
- History of serious drug hypersensitivity
- History of cardiac infarction or congested heart failure of New York Heart Association Classification (NYHA) II or greater within previous 6 months
- Serious illness or concomitant non-oncological disease difficult to be controled by medication, such as active infectious disease, hepatic failure, renal failure, pulmonary fibrosis, interstitial pneumonitis, hemorrhagic tendency, heart disease (congested heart failure, angina, arrhythmia, etc.), uncontrolled, severe hypertension, and diabetes
- Pregnancy or breastfeeding
- Women and men who are sexually active and unwilling to use a medically acceptable method of contraception until 4 weeks after the last trial visit
- Patients positive in tests of hepatitis B (HBs) antigen, hepatitis C (HCV)antibody, or HIV antibody
- Alcohol or drug abuse
- Patient not suitable for participation in this clinical trial in the opinion of the investigator
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: BIBF 1120
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Incidence of Dose Limiting Toxicities (DLT) associated with increasing doses of BIBF 1120
Zeitfenster: Up to 36 months
|
Up to 36 months
|
Incidence and intensity of Adverse Events according to Common Toxicity Criteria (CTCAE Version 3.0) associated with increasing doses of BIBF 1120
Zeitfenster: up to 36 months
|
up to 36 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
maximum tolerated dose (MTD) of BIBF 1120
Zeitfenster: Up to 36 months
|
Up to 36 months
|
Objective tumour response according to the response evaluation criteria in solid tumours (RECIST)
Zeitfenster: Up to 36 months
|
Up to 36 months
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 12 hours after single dose administration (AUC0-12)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 12 hours after the first drug administration
|
Change from baseline in peripheral blood biomarkers
Zeitfenster: Baseline, day 2, day 8, day 30
|
Baseline, day 2, day 8, day 30
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24hours after single dose administration (AUC0-24)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable analyte plasma concentration after single dose administration (AUC0-tz)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single dose administration (AUC0-∞)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
The percentage of the AUCtz-∞ that is obtained by extrapolation (%AUCtz-∞)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Maximum measured concentration of the analyte in plasma following a single dose (Cmax)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Time from dosing to the maximum concentration of the analyte in plasma following a single dose (tmax)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Terminal half-life of the analyte in plasma after single dose administration (t1/2)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Terminal rate constant in plasma after single dose administration (λz)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Mean residence time of the analyte in the body after single dose oral administration (MRTpo)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Apparent clearance of the analyte in plasma after single dose extravascular administration (CL/F)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Apparent volume of distribution during the terminal phase λz following extravascular administration (Vz/F)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after the first drug administration
|
Area under the concentration-time curve of the analyte in plasma at steady state over the time interval from 0 to 24hours (AUC0-24,ss)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Τime from last dosing to the maximum concentration of the analyte in plasma at steady state over a uniform dosing interval τ (tmax,ss)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Terminal half-life of the analyte in plasma at steady state (t1/2,ss)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Terminal rate constant in plasma at steady state (λz,ss)
Zeitfenster: Up to 36 month
|
Up to 36 month
|
Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Predose concentration of the analyte in plasma at steady state immediately before administration of the next dose (Cpre,ss)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Average concentration of the analyte in plasma at steady state (Cavg)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Mean residence time of the analyte in the body at steady state after oral administration (MRTpo,ss)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Apparent clearance of the analyte in plasma at steady state after extravascular multiple dose administration (CL/F,ss)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Apparent volume of distribution during the terminal phase λz at steady state following extravascular administration (Vz/F,ss)
Zeitfenster: before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
before and 0.5, 1, 2, 3, 4, 6, 8, 10 and 24 hours after drug administration
|
Accumulation ratio (RA)
Zeitfenster: Up to 36 month
|
Up to 36 month
|
Predose concentration of the analyte in plasma immediately before administration of the n-th dose (Cpre,n)
Zeitfenster: Day 8, 15 and day 22 after start of treatment
|
Day 8, 15 and day 22 after start of treatment
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Nützliche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 1199.19
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Tumore
-
Incyte CorporationBeendetMalignität eines soliden TumorsVereinigte Staaten, Frankreich, Vereinigtes Königreich, Italien, Korea, Republik von, Japan, Spanien, Israel, Dänemark, Deutschland, Schweiz
-
Martin GutierrezHackensack Meridian Health; Karyopharm Therapeutics IncZurückgezogen
-
Amsterdam UMC, location VUmcAbgeschlossenKnochenmetastasen eines bösartigen TumorsNiederlande
-
Second Affiliated Hospital, School of Medicine,...RekrutierungLeptomeningeale Metastasierung eines soliden TumorsChina
-
Century Therapeutics, Inc.RekrutierungHämatologische Malignität | Malignität eines soliden TumorsVereinigte Staaten
-
Stanford UniversityNational Cancer Institute (NCI)AbgeschlossenPlattenepithelkarzinom des Kopf-Hals-Tumors (SCCHN)Vereinigte Staaten
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityZurückgezogenLokalrezidiv eines bösartigen Tumors der Brust
-
Tianjin Medical University Cancer Institute and...RekrutierungBildqualität und Konturgenauigkeit des Tumors in der StrahlentherapieChina
-
Beijing Chao Yang HospitalRekrutierungLokalrezidiv eines malignen Tumors des Mastdarms | Umlaufender Resektionsrand | Intraoperative Perforation des Rektums | Krankheitsfreies Überleben | GesamtüberlebenChina
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceAktiv, nicht rekrutierendDarmkrebs | Chirurgische Resektion des kolorektalen TumorsFrankreich
Klinische Studien zur BIBF1120
-
Boehringer IngelheimBeendetKarzinom, nicht-kleinzellige LungeJapan
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)AbgeschlossenRezidivierendes Uteruskorpuskarzinom | Klarzelliges Adenokarzinom des Endometriums | Seröses Adenokarzinom des Endometriums | Undifferenziertes Karzinom des Endometriums | Adenokarzinom des Endometriums | Übergangszellkarzinom des Endometriums | Muzinöses Adenokarzinom des Endometriums | Plattenepithelkarzinom... und andere BedingungenVereinigte Staaten
-
Boehringer IngelheimAbgeschlossenProstataneoplasmen
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)AbgeschlossenWiederkehrendes malignes Pleuramesotheliom | Stadium IV PleuramesotheliomVereinigte Staaten
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Boehringer IngelheimAbgeschlossenWiederkehrender nicht-kleinzelliger Lungenkrebs | Nicht-kleinzelliger Lungenkrebs im Stadium IV | Plattenepithelkarzinom der Lunge | Nicht-kleinzelliger Lungenkrebs im Stadium IIIVereinigte Staaten
-
Boehringer IngelheimAbgeschlossenLungenfibroseArgentinien, Australien, Belgien, Brasilien, Bulgarien, Kanada, Chile, China, Tschechische Republik, Frankreich, Deutschland, Griechenland, Ungarn, Irland, Italien, Korea, Republik von, Mexiko, Niederlande, Portugal, Russische... und mehr
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Boehringer Ingelheim; National Comprehensive...AbgeschlossenNintedanib und Capecitabin bei der Behandlung von Patienten mit refraktärem metastasiertem DarmkrebsRezidivierendes Kolonkarzinom | Rezidivierendes Rektumkarzinom | Rektales Adenokarzinom | Dickdarm-Adenokarzinom | Darmkrebs im Stadium IVA | Rektumkarzinom im Stadium IVA | Darmkrebs im Stadium IVB | Rektumkarzinom im Stadium IVBVereinigte Staaten
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkAbgeschlossenKarzinoider Tumor | Neuroendokrine Neoplasie | Metastasierender karzinoider TumorVereinigte Staaten